TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8110564
Drug: Ephedrine infusion
Normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ephedrine infusion titrated between 0 and 120 mg h‐1
Study: 29853660
Drug: AMG 706
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 706 (motesanib) 125 mg per day orally combined with octreotide long acting-repeatable (LAR)
Study: 27193748
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (ZOL) infusion (5 mg)
Study: 23958252
Drug: Anacetrapib (ANA)
Normalized name: Ana-Lex
DrugBank: Anacetrapib (DB06630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anacetrapib (ANA) co-administered with atorvastatin (ATV) 10 mg
Study: 3214495
Drug: Lomefloxacin 400
Normalized name: lomefloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lomefloxacin 400 mg
Study: 20514832
Drug: Chewing gum
Normalized name: Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chewing gum (sugarless) for 30 minutes thrice daily until resumption of intestinal transit
Study: 6324616
Drug: Captopril 3
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril 3 mg/kg po
Study: 11135227
Drug: Intratumoral injection
Normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intratumoral injection of 30 million autologous dendritic cells (DCs) per tumor after treatment with granulocyte‐macrophage‐colony stimulating factor and interleukin‐4.
Study: 18751497
Drug: Amlodipine besylate
Normalized name: Amlodipine Besylate
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine besylate test formulation (10 mg)
Study: 7738215
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of ranitidine (150 mg/24 hr)
Study: 7738215
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of famotidine (40 mg/24 hr)
Study: 30971750
Drug: Apple juice
Normalized name: apple juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apple juice treated with invertase, glucose oxidase/catalase (glucose 0.05 g; gluconate 18.2 g)
Study: 1706014
Drug: Enalapril 20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 20 mg
Study: 24634462
Drug: Nicotine Replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine Replacement Therapy (NRT) - 15 mg/16 hr nicotine patches
Study: 10987706
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with histories of injection drug abuse
Study: 12888588
Drug: Meglumine antimoniate
Normalized name: meglumine antimoniate
DrugBank: Meglumine antimoniate (DB13732)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meglumine antimoniate 20 mg Sbv/kg/day for 28 days
Study: 20423278
Drug: Yuzpe regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yuzpe regimen (high dose combined oral contraceptive pills)
Study: 24457472
Drug: Arterial infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arterial infusion of p53 gene (Gendicine)
Study: 16796078
Drug: Fenofibrate 130
Normalized name: fenofibrate 130 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate 130 mg/day
Study: 15203786
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nicotine skin patches and mecamylamine
Study: 21566232
Drug: NeuroFlo treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: NeuroFlo treatment
Study: 26539650
Drug: rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 10 mg
Study: 20361676
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium iron edetate (SIE)
Study: 23771193
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg single dose in postbariatric surgery group
Study: 2203486
Drug: Oral RO
Normalized name: ALCOHOL 70 mL in 100 mL TOPICAL GEL [Floral rose scented hand sanitizer 01]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral RO 42-5892 (600 mg)
Study: 2110787
Drug: Intramuscular lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular lorazepam
Study: 17565435
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg melatonin
Study: 7978533
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of H1 and H2 histamine antagonists and a corticosteroid in gelatin capsules
Study: 7978533
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (premedication)
Study: 29802636
Drug: Basal-bolus therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal-bolus therapy
Study: 1623908
Drug: Clonidine 200
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine 200 micrograms orally + naloxone i.v. (2.8 mg/5 h)
Study: 12814448
Drug: Levosimendan administered
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan administered by intravenous infusion
Study: 18028044
Drug: Fentanyl iontophoretic
Normalized name: fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl iontophoretic transdermal system (ITS) (40 microg fentanyl/dose)
Study: 12013151
Drug: Chondroitin sulfate
Normalized name: Chondroitin Sulfate
DrugBank: Chondroitin sulfate (DB09301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chondroitin sulfate 800 mg/day plus naproxen 500 mg/day
Study: 1677267
Drug: Topical bunazosin
Normalized name: bunazosin
DrugBank: Bunazosin (DB12230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical bunazosin 0.3%
Study: 9926031
Drug: Psychological treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological treatments
Study: 19335074
Drug: 0.3 mg/ml
Normalized name: menthol 0.3 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/ml rhPDGF‐BB + beta‐TCP + bioabsorbable collagen wound‐healing dressing
Study: 9923576
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive formulation containing 0.125 mg levonorgestrel and 0.03 mg ethinylestradiol (group B)
Study: 20389106
Drug: High-fat meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat meal (fat content: 38 g, energy content: 640 kcal)
Study: 3770273
Drug: Intravenous calcium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous calcium infusion (calcium gluconate 36.3 mEq/5 h)
Study: 6851564
Drug: ONO 802
Normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO 802 pessaries (1 mg of 16, 16-dimethyl-trans-delta 2-prostaglandin E1 methyl ester)
Study: 31064405
Drug: Enoxaparin 20
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 20 mg
Study: 28229275
Drug: Active Treatment
Normalized name: Active
DrugBank: Octisalate (DB11062)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active Treatment Group (prebiotic vaginal moisturizer)
Study: 2316795
Drug: Government Pharmaceutical
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Government Pharmaceutical Organization of Thailand antivenom (mostly F(ab)2 fragments)
Study: 9702644
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone therapy (0.2 U/kg subcutaneously daily for 28 days)
Study: 29284596
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy
Study: 23963102
Drug: Tamsulosin 0.4
Normalized name: tamsulosin 0.4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.4 mg/day
Study: 3326678
Drug: Meclofenamate sodium
Normalized name: Meclofenamate Sodium
DrugBank: Meclofenamic acid (DB00939)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meclofenamate sodium 100 mg
Study: 20350344
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (FO) supplemented parenteral nutrition (PN)
Study: 28340570
Drug: Vacc-C5 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vacc-C5 vaccine administered intramuscularly with Alhydrogel or intradermally with GM-CSF as adjuvant
Study: 28340570
Drug: Vacc-C5 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vacc-C5 vaccine
Study: 23058047
Drug: Halofantrine (HF)
DrugBank: Halofantrine (DB01218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Halofantrine (HF) 72 mg/kg (8 mg/kg every 6 to 10 h for 3 days)
Study: 23058047
Drug: Healthy volunteers
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy volunteers (HF doses of 250, 500, and 1000 mg)
Study: 16253965
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist administration
Study: 11605932
Drug: Combined spinal-epidural
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined spinal-epidural analgesia (10 microg intrathecal sufentanil with or without 2.0 mg bupivacaine, n = 1,071)
Study: 11605932
Drug: Epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural analgesia (10 microg epidural sufentanil and 12.5-25.0 mg bupivacaine, n = 1,112)
Study: 23708326
Drug: BCAA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA treatment
Study: 17319037
Drug: Topical clobetasol
Normalized name: clobetasol Topical Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical clobetasol propionate 0.05% cream
Study: 22234244
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab (IVB) 1.25 mg
Study: 26829251
Drug: Nifedipine monotherapy
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine monotherapy
Study: 8473427
Drug: Long treatment
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long treatment protocol (buserelin administered from mid-luteal phase)
Study: 12953327
Drug: Transdermal patches
Normalized name: MENTHOL 0.3 g in 100 TOPICAL PATCH [Aroamas Cot Nicotine Transdermal Patches]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal patches releasing estradiol (E2) and progestogen for HRT
Study: 12385443
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg SP-303
Study: 16121513
Drug: KanJang oral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: KanJang oral solution (fixed combination of Echinacea purpurea, Adhatoda vasica, and Eleutherococcus senticosus)
Study: 9681586
Drug: Flunitrazepam 2
Normalized name: flunitrazepam 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam 2 mg (FNZ2N)
Study: 22418764
Drug: Low concentration
Normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low concentration of heparin (LCH) 2,500 IU/ml
Study: 11281052
Drug: Granulocyte Colony-Stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte Colony-Stimulating Factor (rhG-CSF) 5 micrograms/kg/day subcutaneous as a supplement to antibiotherapy
Study: 22753019
Drug: Colchicine 0.6
Normalized name: colchicine 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine 0.6 mg single dose in young subjects
Study: 9657564
Drug: Specific immunotherapy
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific immunotherapy
Study: 17409368
Drug: Physician defying
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Physician defying DSS recommendation with less aggressive treatment
Study: 17409368
Drug: Physician defying
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Physician defying DSS recommendation with more aggressive treatment
Study: 16100184
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone dipropionate (BDP) at doses > 100 microg
Study: 11517852
Drug: Placentrex treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placentrex treatment
Study: 27291249
Drug: Grazoprevir 100
Normalized name: grazoprevir 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grazoprevir 100 mg once daily and Ribavirin for 24 weeks
Study: 9663357
Drug: Irbesartan 300
Normalized name: irbesartan 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan 300 mg once daily (after dose doubling if SeDBP >= 90 mm Hg)
Study: 27804233
Drug: Irbesartan treatment
Normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Irbesartan treatment
Study: 31035117
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone gel
Study: 12377810
Drug: Hypnotic relaxation
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic relaxation
Study: 28678148
Drug: Levosimendan (No-L-group)
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan (No-L-group)
Study: 16255132
Drug: Bevacizumab (Avastin)
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab (Avastin) as a component of first-line treatment
Study: 16255132
Drug: Cetuximab (Erbitux)
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab (Erbitux) in standard first-line chemotherapy
Study: 15963077
Drug: Rifaximin 600
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifaximin 600 mg/day
Study: 10741936
Drug: Rifaximin 2400
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifaximin 2400 mg/day
Study: 15592697
Drug: Low-dose-rate (LDR)
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose-rate (LDR) brachytherapy
Study: 30054636
Drug: Positive CTC
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive CTC assay result in hormone receptor-negative disease
Study: 21316048
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) 50 mg/d
Study: 1982108
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg nizatidine BID
Study: 2269924
Drug: Silver sulfadiazine
Normalized name: Silver Sulfadiazine
DrugBank: Silver sulfadiazine (DB05245)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silver sulfadiazine and hydrocortisone cream 1% (used in combination)
Study: 6102442
Drug: Chlorpheniramine maleate
Normalized name: Chlorpheniramine Maleate
DrugBank: Chlorpheniramine (DB01114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine maleate 4 mg tid
Study: 30764805
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D therapy (800 IU cholecalciferol daily)
Study: 8489569
Drug: Diclofenac-sucralfate association
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diclofenac-sucralfate association (50 mg)
Study: 8489569
Drug: Enteric-coated tablets
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated tablets (50 mg)
Study: 31615934
Drug: EUS examination
Normalized name: chlorine dioxide
DrugBank: Chlorine dioxide (DB12453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EUS examination after 3-5 mL submucosal saline injection (SSI)
Study: 19394618
Drug: Atorvastatin 80mg
Normalized name: AMLODIPINE 5MG/ATORVASTATIN 80MG TAB
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin 80mg daily
Study: 19875309
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of ramipril until the morning of surgery and vasopressin infusion (Group C)
Study: 29110696
Drug: Topical tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical tranexamic acid (TXA)
Study: 31480553
Drug: Caffeine supplement
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine supplement (CAF; 6 mg∙kg‐1)
Study: 30219920
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment
Study: 10793878
Drug: E2 1
Normalized name: PGE2 10 MG Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2 1 mg/NETA 0.25 mg
Study: 3497990
Drug: PRP-D vaccine
Normalized name: Hib (PRP-D)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP-D vaccine
Study: 3549393
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose of PRP-D
Study: 22796139
Drug: VAX128 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAX128 vaccine (various constructs)
Study: 12571693
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of beta-blockers
Study: 30795705
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 250 µg twice daily (BD)
Study: 15312254
Drug: Pravastatin and
Normalized name: pravastatin and ezetimibe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin and nonstatin cholesterol-lowering drugs
Study: 31658542
Drug: Silver sulfadiazine
Normalized name: Silver Sulfadiazine
DrugBank: Silver sulfadiazine (DB05245)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silver sulfadiazine cream with dressing change every other day
Study: 26888240
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of semilunar coronally advanced flap (SCAF) and button technique
Study: 27743432
Drug: Multispecies probiotic
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multispecies probiotic supplements
Study: 2403123
Drug: Bicarbonate infusion
Normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicarbonate infusion (1.3%)
Study: 28234053
Drug: BI 671800
Normalized name: BI-671800
DrugBank: BI-671800 (DB12524)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 671800 400 mg P.M. with fluticasone propionate
Study: 22987572
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg rosuvastatin
Study: 16322140
Drug: Multisystemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multisystemic therapy (MST)
Study: 31462933
Drug: Both drugs
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both drugs
Study: 30587955
Drug: O2matic-controlled treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: O2matic-controlled treatment
Study: 17224017
Drug: Audio-tape with
Normalized name: E-Z Scrub with Ultradex Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Audio-tape with relevant information regarding implant insertion
Study: 21687997
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of MG and SOL
Study: 31843975
Drug: C1 esterase
Normalized name: C1 esterase
Approvals — FDA: no, EMA: no, PMDA: no
Description: C1 esterase inhibitor 50 U/kg
Study: 7197583
Drug: Cisplatin 90
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 90 mg/m2 every 3 weeks
Study: 20974320
Drug: Midazolam 50
Normalized name: midazolam 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 50 µg/kg IV
Study: 20974320
Drug: Midazolam 75
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam 75 µg/kg IV
Study: 10381787
Drug: 15 mg/day
Normalized name: Climara Pro 0.045/0.015 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/day meloxicam
Study: 7536380
Drug: Digital rectal
Normalized name: BD Thermometer Digital Rectal (obsolete)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital rectal examination 24 hours before the second PSA determination
Study: 1699653
Drug: CHOP +
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CHOP + low-dose bleomycin
Study: 1341478
Drug: Interferon alone
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alone therapy
Study: 29140808
Drug: AGE with
Normalized name: zinc bandage with supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGE with supplements (AGE+S)